Enteropathy associated T-cell lymphoma and its precursor lesions

Area of Science:

• Gastroenterology
• Oncology
• Hematology

Background:

• Enteropathy Associated T-cell Lymphoma (EATL) is an intra-epithelial lymphocyte intestinal tumor.
• EATL is classified into two types: Type I, associated with Celiac Disease (CD), and Type II, without CD association.
• Both types present distinct clinical and pathological features, impacting diagnostic and therapeutic approaches.

Purpose of the Study:

• To review the current understanding of Enteropathy Associated T-cell Lymphoma (EATL).
• To highlight diagnostic work-up and treatment modalities for EATL.
• To emphasize the need for improved therapeutic strategies and future research directions.

Main Methods:

• Diagnostic work-up includes video capsule enteroscopy (VCE), double-balloon enteroscopy (DBE), CT, 18F-FDG-PET scans, and magnetic resonance enteroclysis (MRE).
• Current treatments involve chemotherapy, tumor resection, and stem cell transplantation.
• Review of existing literature on EATL classification, diagnosis, and treatment outcomes.

Main Results:

• EATL Type I presents with malabsorption and CD symptoms, while Type II often causes obstruction or perforation.
• Current treatment regimens yield a poor 5-year survival rate of 8-20%.
• Despite aggressive therapies, outcomes for EATL patients remain suboptimal.

Conclusions:

• EATL requires a comprehensive diagnostic approach for accurate classification and staging.
• Existing treatments for EATL are insufficient, leading to poor prognoses.
• Prospective multicenter trials investigating novel therapies, such as combinations of chemotherapy, monoclonal antibodies, and small molecules, are crucial for improving EATL survival rates.